Pipeline

Voyager is developing novel and complementary approaches to disrupt the progression of tau pathology to address tauopathies including Alzheimer’s disease. We believe our passive-immunity therapeutic and vectorized anti-tau antibodies are highly differentiated from competitive approaches by offering improved targeting of specific regions of the tau protein that could offer an improved clinical profile compared to first generation approaches.

Up to 10% of Parkinson’s disease (PD) patients have a GBA1 mutation, which increases the risk of PD approximately 20-fold. Voyager is leveraging gene replacement technology to address PD with GBA1 mutations. Our approach is designed for delivery of GBA1 via intravenous AAV dosing to enable widespread distribution to multiple affected brain regions and avoid the need for more invasive approaches.

Superoxide dismutase 1 (SOD1) mutations cause toxic gain of function in forms of familial amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease with minimally effective treatments. Voyager’s SOD1 knockdown program aims to address ALS caused by SOD1 mutations by combining a highly potent siRNA construct with a CNS-tropic, BBB penetrant capsid identified from Voyager’s TRACER platform, allowing for intravenous AAV dosing to enable broad CNS knockdown of SOD1 and slow of the decline of functional ability.